Abstract
Festive gatherings this 2020 holiday season threaten to cause a surge in new cases of novel coronavirus disease 2019 (COVID-19). Hospitals and long-term care facilities are key hotspots for COVID-19 outbreaks, and may be at elevated risk as patients and staff return from holiday celebrations in the community. Some settings and institutions have proposed fortified post-holiday testing regimes to mitigate this risk. We use an existing model to assess whether implementing a single round of post-holiday screening is sufficient to detect and manage holiday-associated spikes in COVID-19 introductions to the long-term care setting. We show that while testing early helps to detect cases prior to potential onward transmission, it likely to miss a substantial share of introductions owing to false negative test results, which are more probable early in infection. We propose a two-stage post-holiday testing regime as a means to maximize case detection and mitigate the risk of nosocomial COVID-19 outbreaks into the start of the new year. Whether all patients and staff should be screened, or only community-exposed patients, depends on available testing capacity: the former will be more effective, but also more resource-intensive.
Competing Interest Statement
LO reports grants from Pfizer, outside the submitted work. All other authors report no competing interests.
Funding Statement
The work was supported by the French National Research Agency (ANR) project MOD-COV (ANR-20-COVI-0071). DS is supported by a Canadian Institutes of Health Research Doctoral Foreign Study Award (Funding Reference Number 164263) as well as the ANR project SPHINX-17-CE36-0008-01.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used inter-individual contact data from the i-Bird study, which obtained all authorizations in accordance with French regulations regarding medical research and information processing. All French IRB-equivalent agencies accorded the i-Bird program official approval (CPP 08061; Afssaps 2008-A01284-51; CCTIRS 08.533; CNIL AT/YPA/SV/SN/GDP/AR091118 N 909036). Signed consent by patients and staff was not required according to the French Ethics Committee to which the project was submitted.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Simulated data is available from authors upon reasonable request.
